4BIO Capital appoints Brian P. McVeigh as Venture Partner

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Press Release

Image result for 4bio capital

4BIO Capital appoints Brian P. McVeigh as Venture Partner

Appointment of seasoned pharma and biotech industry veteran to strengthen 4BIO Capital’s US operations

1 July 2020

LONDON & PHILADELPHIA – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces that it has appointed Brian P. McVeigh as Venture Partner based in the US.

Dmitry Kuzmin, Managing Partner at 4BIO Capital, said: “We are pleased to welcome Brian to the ever-expanding 4BIO team. It is well known that the Mid-Atlantic region is one of the global hotspots for the advanced therapies field so the addition of a Venture Partner based in Philadelphia, particularly with Brian’s extensive experience and network in the pharmaceutical industry, will be invaluable as we continue our efforts to identify and invest in innovative opportunities in the most exciting fields of medicine.”

Brian P. McVeigh said: “I have dedicated my entire career to the advancement of innovative and transformative medicines, initially in big pharma at GSK and more recently in management and advisory positions at several dynamic biotechnology companies. I am excited to be joining the first Venture Capital fund focused solely on advanced therapy investments, and I look forward to enhancing 4BIO’s access to the highly exciting innovation and science in the burgeoning advanced therapies sector in the US.”

Brian has over 28 years’ experience in the life sciences industry with a proven track record of defining strategies, building high performing teams, and successfully executing on delivery. Before transitioning into biotech Brian enjoyed a 25-year career with GlaxoSmithKline (GSK) where he held multiple senior-level positions within the global Business Development, Finance, Marketing, Corporate and R&D organizations. While with GSK he most recently served as the Vice President of Worldwide Business Development Transactions and Investment Management, during which he personally led the assessment, negotiation, and execution of over two-dozen major transactions and directed a global team that delivered on the execution of over 100 business development transactions. He also managed GSK’s equity investments in R&D collaboration partners and GSK’s Limited Partner investments in venture capital funds, a portfolio totaling >$500 million of invested and committed capital which delivered >$650 million of realized financial returns while under his leadership.

Brian is currently the Executive Chairman of Code BioTherapeutics, a biotechnology company he co-founded that is pioneering targeted non-viral gene therapies as potential cures for rare monogenic disorders. He also serves as Executive Chairman of Genisphere, a life sciences company with commercial products in microRNA assays and labelling kits as well as investments in drug delivery and allergy diagnostics technology platforms. 

Prior to this Brian was Chief Business Officer at Zafgen Inc, a NASDAQ listed clinical-stage biopharmaceutical company developing potentially transformative therapies for patients affected by a range of rare metabolic diseases. Here, he led corporate strategy, business development and new product planning activities, was involved in the $69 million follow-on public offering in July 2018, and led the merger with Chondrial Therapeutics to form the new rare disease focused company Larimar Therapeutics in May 2020.  -End-


4BIO Capital+44 (0) 203 427 5500 [email protected]
AccessAlpha Worldwide LLC Investment relations – North America+1 (312) 585 6000 [email protected]
Consilium Strategic Communications Amber Fennell, Olivia Manser, Lizzie Seeley, Maya Bennison+44 (0)20 3709 5700 [email protected]


About 4BIO Capital

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.

4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.

The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.

For more information, please visit www.4biocapital.com

Primary Logo